B2B
The company developing Myrcludex B, a first-in-class drug for the treatment of chronic hepatitis B (HBV) and chronic hepatitis delta (HDV).
myr-pharma.com
The company developing Myrcludex B, a first-in-class drug for the treatment of chronic hepatitis B (HBV) and chronic hepatitis delta (HDV).
myr-pharma.com
Location: Germany, Hesse, Bad Homburg vor der Höhe
Total raised: $711.09K
Investors 2
| Date | Name | Website |
| - | Joint Jour... | jj.capital |
| - | High-Tech ... | htgf.de |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 12.05.2011 | - | $711.09K | High-Tech ... |
Mentions in press and media 3
| Date | Title | Description |
| 04.11.2014 | MYR Raises $10M | MYR GmbH, a Burgwedel, Germany-based biotechnology company, raised $10m in funding. Backers included Maxwell Biotech Venture Fund and High-Tech Gruenderfonds. The company intends to use the funds for the further product development of Myrcl... |
| 12.05.2011 | MYR Receives €500K Equity Investment from High-Tech Gründerfonds | MYR GmbH, a Burgwedel (Hannover), Germany-based biotech company that develops a drug for the treatment of chronic hepatitis B and D infections, has received a €500k equity investment from High-Tech Gründerfonds. The company will use the fun... |
| - | Most Successful Exit in the History of High-Tech Gründerfonds – Gilead Sciences to Acquire MYR GmbH | Gilead Sciences, Inc. (Nasdaq: GILD) and MYR GmbH (MYR) announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MYR for approximately €1.15 bn in cash, payable upon closing of the transact... |